Genenta Science Aktie - GNTA

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Premium

Current Price

4,15

Gebot

3,35

Fragen

5,93

Volumen

9.027

3,98 Tagesbereich 4,15

0,00 52-Wochen-Bereich 0,00

Marktkapitalisierung

75,6M

Handelsende

3,92

Handelsbeginn

3,98

Letzte Trade

4.14

Letzter Handelszeitpunkt

Finanzvolumen

US$ 37.087

VWAP

4,1084

Durchschnittliches Volumen (3 Mio.)

Ausgegebene Aktien

18.216.958

Dividendenrendite

Kurs-Gewinn-Verhältnis

-7,12

Gewinn pro Aktie (EPS)

-0,58

Erlöse

465k

Nettogewinn

-10,62M

Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's product under development includes Temferon - a product to treat glioblastoma multiforme, a solid tumor affec... Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's product under development includes Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain, and TEMs -Immuno-Gene Therapy. Mehr anzeigen

Sektor

Health Practitioners, Nec

Branche

Health Practitioners, Nec

Website

www.genenta.com

Hauptsitz

Milan, Lombardy, Ita

Gegründet

Genenta Science SPA is listed in the Health Practitioners sector of the NASDAQ with ticker GNTA. The last closing price for Genenta Science was US$3,92. Over the last year, Genenta Science shares have traded in a share price range of US$ 0,00 to US$ 0,00.

Genenta Science currently has 18.216.958 shares in issue. The market capitalisation of Genenta Science is US$71,41 million. Genenta Science has a price to earnings ratio (PE ratio) of -7.12.

Genenta Announces €20 million ($21.9M) Financing To Expand Pipeline As Brain Tumor Trial Is Showing Promising Survival Rates

MILAN and NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a pioneer in...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Oncology Breakthroughs: How Cancer Research Is Advancing in 2025

Oncology Breakthroughs: How Cancer Research Is Advancing in 2025 PR Newswire VANCOUVER, BC, Feb. 27, 2025 USA...

Oncology Breakthroughs: How Cancer Research Is Advancing in 2025

Oncology Breakthroughs: How Cancer Research Is Advancing in 2025 PR Newswire VANCOUVER, BC, Feb. 27, 2025 USA...

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

TOP ITALIAN AND U.S. LIFE SCIENCES EXECUTIVES AND ITALIAN GOVERNMENT LEADERS SHARED BUSINESS SUCCESS STORIES WITH INVESTORS AT "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE

TOP ITALIAN AND U.S. LIFE SCIENCES EXECUTIVES AND ITALIAN GOVERNMENT LEADERS SHARED BUSINESS SUCCESS STORIES...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

GNTA - Frequently Asked Questions (FAQ)

What is the current Genenta Science share price?

The current share price of Genenta Science is US$ 4,15

How many Genenta Science shares are in issue?

Genenta Science has 18.216.958 shares in issue

What is the market cap of Genenta Science?

The market capitalisation of Genenta Science is USD 71,41M

What is the 1 year trading range for Genenta Science share price?

Genenta Science has traded in the range of US$ 0,00 to US$ 0,00 during the past year

What is the PE ratio of Genenta Science?

The price to earnings ratio of Genenta Science is -7,12

What is the cash to sales ratio of Genenta Science?

The cash to sales ratio of Genenta Science is 162,75

What is the reporting currency for Genenta Science?

Genenta Science reports financial results in EUR

What is the latest annual turnover for Genenta Science?

The latest annual turnover of Genenta Science is EUR 465k

What is the latest annual profit for Genenta Science?

The latest annual profit of Genenta Science is EUR -10,62M

What is the registered address of Genenta Science?

The registered address for Genenta Science is VIA OLGETTINA, 58, 430 EAST 29TH STREET, MILAN, LOMBARDY, 20132

What is the Genenta Science website address?

The website address for Genenta Science is www.genenta.com

Which industry sector does Genenta Science operate in?

Genenta Science operates in the HEALTH PRACTITIONERS, NEC sector

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
SGLYSingularity Future Technology Ltd	US$ 1,6799 (143,43%)	30,76M
WINVWinVest Acquisition Corporation	US$ 25,00 (107,30%)	463
VVPRVivoPower International PLC	US$ 1,2899 (52,13%)	65,08M
RNAZTransCode Therapeutics Inc	US$ 1,12 (45,45%)	216,22M
GLTOGalecto Inc	US$ 6,00 (44,93%)	10,71M
YHCLQR House Inc	US$ 0,40 (-82,38%)	38,32M
KZIAKazia Therapeutics Ltd	US$ 0,9759 (-80,02%)	55,66k
DMNDamon Inc	US$ 0,0373 (-70,02%)	304,17M
TCBPTC BioPharm Holdings PLC	US$ 0,5046 (-67,23%)	5,9M
SOWGSow Good Inc	US$ 1,53 (-44,36%)	698,02k
DMNDamon Inc	US$ 0,0373 (-70,02%)	304,17M
NVDANVIDIA Corporation	US$ 117,70 (-0,70%)	264,42M
RNAZTransCode Therapeutics Inc	US$ 1,12 (45,45%)	216,22M
TSLLDirexion Daily TSLA Bull 2X Trust ETF	US$ 9,03 (10,66%)	175,77M
HOLOMicroCloud Hologram Inc	US$ 1,00 (32,36%)	141,98M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Genenta Science SPA (GNTA) Börsenkurse

Genenta Science SPA (GNTA)

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Wichtige Statistiken und Details

Über Genenta Science SPA

GNTA Neueste Nachrichten

Genenta Announces €20 million ($21.9M) Financing To Expand Pipeline As Brain Tumor Trial Is Showing Promising Survival Rates

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Oncology Breakthroughs: How Cancer Research Is Advancing in 2025

Oncology Breakthroughs: How Cancer Research Is Advancing in 2025

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

TOP ITALIAN AND U.S. LIFE SCIENCES EXECUTIVES AND ITALIAN GOVERNMENT LEADERS SHARED BUSINESS SUCCESS STORIES WITH INVESTORS AT "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE

Genenta Strengthens Agreement with AGC Biologics to Boost Cell Therapy Manufacturing

ITALIAN TRADE AGENCY TO HOST "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Genenta Announces €20 million ($21.9M) Financing To Expand Pipeline As Brain Tumor Trial Is Showing Promising Survival Rates

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Oncology Breakthroughs: How Cancer Research Is Advancing in 2025

Oncology Breakthroughs: How Cancer Research Is Advancing in 2025

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

TOP ITALIAN AND U.S. LIFE SCIENCES EXECUTIVES AND ITALIAN GOVERNMENT LEADERS SHARED BUSINESS SUCCESS STORIES WITH INVESTORS AT "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE

Genenta Strengthens Agreement with AGC Biologics to Boost Cell Therapy Manufacturing

GNTA - Frequently Asked Questions (FAQ)

Beweger

GNTA Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR